Premium
Treatment of acute myocardial ischaemia with a selective antagonist of thromboxane receptors (BM 13.177)
Author(s) -
Schrör Karsten,
Thiemermann Christoph
Publication year - 1986
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.1986.tb14579.x
Subject(s) - thromboxane a2 , thromboxane , medicine , thromboxane a synthase , ischemia , antagonist , receptor antagonist , platelet , cardiology , pharmacology , receptor , endocrinology
1 In order to elucidate the role of endogenous thromboxane A 2 in myocardial ischaemia, cats were subjected to 5 h of permanent occlusion of the left anterior descending coronary artery (LAD) and treated with the thromboxane receptor antagonist BM 13.177 (5 mg kg −1 h −1 , i.v.). 2 In comparison with vehicle‐treated LAD‐occluded cats, BM 13.177 significantly attenuated the loss of creatine phosphokinase‐specific activity from the ischaemic myocardium and antagonized the ischaemia‐induced rise in the ST‐segment of the electrocardiogram. 3 BM 13.177 at the dose used did not reduce plasma thromboxane levels or ischaemia‐induced platelet aggregate formation but considerably antagonized thromboxane‐dependent platelet secretion ex vivo . 4 The study demonstrates some beneficial effects of selective blockade of thromboxane receptors on biochemical and electrophysiological parameters of acute myocardial ischaemia.